Kiwi I don’t see any scientific reason to expect Vascepa to be less effective against the Delta variant or any other variant. If the Delta variant has a mutation in the antibody binding site that reduces the antibodies ability to attach (and flag the immune system to attack) then the virus is allowed to reproduce and spread.
If Vascepa has direct antiviral properties it is likely because it causes membrane destabilization which kills the virus. This would not be affected by a change in the antibody binding site.
If Vascepa works by restoring balance to the immune system and prevents an overreaction of the inflammatory portion of the immune response this again would not be altered because the virus has an altered binding site.
Because neither of the two above mentioned mechanisms of action rely on anything specific to the Covid SARS-Cov-2 virus itself this is why Vascepa would likely be effective in the flu sepsis and many other immune dysregulation conditions.
As for your earlier question, I have no idea which variant is the primary infection in Argentina
A drug that combats CV19 with anti-inflammatory activity should not have different results for various strains unless a variant causes different medical problems, something not in evidence. Vaccine efficacy is a different animal to treatment efficacy. I hope we see V helps at least a little bit, but I'm not counting on it - may not be enough severe cases to get stat sig data - and I don't believe V will have any efficacy in preventing infection, MOA doesn't match.
And yeah, scripts are depressing, worse than last year and no growth in the combined market. Even worse, check out this plot by Captbeer - the refill rate dropped by -23% AFTER the R-IT results came out - how the hell does that make sense?
News 
Market Data 
Discover 
AI
